Close Menu

credit facility

The firm expects to offer nearly 5 million shares and also noted that this week it entered into an amended credit facility.

NanoString will initially draw $60 million at close, which will net it approximately $8 million after repaying its existing debt with the investment firm.

The new agreement amends a deal reached in October to partially fund its acquisition of some Alere businesses. That agreement was for $270 million.

NeoGenomics has now redeemed 100 percent of the $110 million preferred stock issues in conjunction with the Clarient acquisition, at a cost of $105 million.

The company said it will use the proceeds for technology development and to expand its global footprint, among other things.

The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.

The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.

The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.

The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.

Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.